Zyla Life Sciences
ZCOR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ZCOR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Market Cap
—
Cash Runway
—
Lead Asset
egalet-002 (Preclinical)
Next Catalyst
—
Financial data as of Mar 31, 2020.
Tracking 6 pipeline candidates · 1 FDA decision for Zyla Life Sciences.
Run Zyla Life Sciences through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Zyla Life Sciences facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 8.29
Lead: Approved
6 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is Zyla Life Sciences's lead drug candidate?
Zyla Life Sciences's most advanced tracked candidate is egalet-002 (Preclinical) for Pain.
Who is the CEO of Zyla Life Sciences?
Assertio Therapeutics is the chief executive officer of Zyla Life Sciences (ZCOR).
What therapeutic areas does Zyla Life Sciences focus on?
Zyla Life Sciences develops therapies across Immunology, Metabolic, Pain, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.